Turning promising science into something the market understands and believes in is rarely straightforward. Leila de Koster shares how Hale navigated the realities of building a novel therapeutic category from the ground up, overcoming entrenched assumptions, earning trust across investors, regulators, and the veterinary market, and reaching the development and funding milestones that demonstrate the category is real.